BeyondSpring Inc. Deferred Income Tax Expense (Benefit)
BeyondSpring Inc. (BYSI) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-25
- BeyondSpring Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- BeyondSpring Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- BeyondSpring Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2022-12-31 | $0.00 20-F · filed 2023-04-18 |
| 2021-12-31 | $0.00 20-F · filed 2023-04-18 |
| 2020-12-31 | $0.00 20-F · filed 2023-04-18 |
| 2019-12-31 | $0.00 20-F · filed 2022-04-14 |
| 2017-12-31 | $0.00 20-F · filed 2018-04-03 |
| 2016-12-31 | $0.00 20-F · filed 2018-04-03 |
| 2015-12-31 | $0.00 20-F · filed 2018-04-03 |
| 2014-12-31 | $0.00 20-F · filed 2017-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |